This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Emergent (EBS) Down on Unfavorable Patent Ruling on Narcan
by Zacks Equity Research
Emergent's (EBS) stock falls after a district court rules against the patent litigation on its Narcan nasal spray product. The court ruled in favor of Teva Pharmaceuticals, the defendants.
Stocks & ETFs Beneficiaries of Coronavirus Vaccine Ramp-Up
by Sanghamitra Saha
Efforts in formulating a coronavirus vaccine are heating up. These stocks and ETFs look to be the largest beneficiaries.
Emergent (EBS) Earnings and Revenues Beat Estimates in Q1
by Zacks Equity Research
Emergent's (EBS) earnings and revenues surpass estimates in the first quarter of 2020. The company reaffirms its guidance for the ongoing year.
Vaxart (VXRT) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
During Vaxart's (VXRT) upcoming Q1 earnings call, investor focus will be on the company's progress with its oral vaccine candidates against SARS CoV-2.
Vaxart Up on Pre-Clinical Data on Coronavirus Vaccine Candidates
by Zacks Equity Research
Vaxart's (VXRT) several COVID-19 vaccine candidates generate immune responses in pre-clinical studies. Stock rises.
Biotech Stock Roundup: ALXN, MRNA Up on Coronavirus Treatment Updates, & More
by Zacks Equity Research
The biotech sector is in focus with pipeline updates from companies evaluating treatments for the novel COVID-19.
Company News for Apr 22, 2020
by Zacks Equity Research
Companies In The News Are: SYF, VXRT, PAVM, WAFD
The Zacks Analyst Blog Highlights: Regeneron Pharmaceuticals, Moderna, Sanofi, Vaxart and Eli Lilly
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Regeneron Pharmaceuticals, Moderna, Sanofi, Vaxart and Eli Lilly
Buy 5 Top Medical Stocks on Coronavirus Drug Trial Results
by Nalak Das
The whole world has pinned hopes on pharmaceutical and biotech companies to create drugs and vaccine to help combat COVID-19.
4 Cheap Stocks to Buy on Signs of Coronavirus Slowdown
by Shuvra Shankar Dey
The highly oversold market offers some ultra-cheap stocks with stellar prospects as the coronavirus pandemic shows signs of slowing down.
The Zacks Analyst Blog Highlights: Co-Diagnostics, VAXART, Zoom Video, CrowdStrike and Domino's
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Co-Diagnostics, VAXART, Zoom Video, CrowdStrike and Domino's
Top Sectors of Q1 & Their Winning Stocks
by Sanghamitra Saha
Inside the top-performing sectors of Q1 and their winning stocks.
Coronavirus Drug Development Race to Boost These 4 Stocks
by Zacks Equity Research
Fast-track approval for coronavirus drug trials is encouraging drug developers. Here are four stocks that can make the most of this phase.
The Zacks Analyst Blog Highlights: Vaxart, Zoom Video Communications, Amazon.com, Clorox and Costco Wholesale
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Vaxart, Zoom Video Communications, Amazon.com, Clorox and Costco Wholesale
Top Ranked Momentum Stocks to Buy for March 25th
by Zacks Equity Research
Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, March 25th
Here're the 5 Big Winners from the Coronavirus Pandemic
by Tirthankar Chakraborty
Even though several companies have suffered badly from the COVID-19 outbreak, here're five that stand to benefit from the pandemic.
Emergent (EBS) to Help Vaxart Develop Coronavirus Vaccine
by Zacks Equity Research
Emergent BioSolutions (EBS) teams up with Vaxart to support development of the latter's oral vaccine candidate for treating coronavirus disease.
Top Ranked Momentum Stocks to Buy for March 19th
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, March 19th
Biotech Stock Roundup: MRNA & REGN Gain on Coronavirus Treatment Updates & More
by Zacks Equity Research
The biotech sector is in focus with pipeline updates from companies evaluating treatments for the novel COVID-19.
Top Ranked Momentum Stocks to Buy for March 17th
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, March 17th
5 Reasons to Buy These Small-Cap Stocks Now
by Sanghamitra Saha
After a painful stretch, small-cap U.S. stocks should rebound on a few tailwinds.
3 Correction-Defying Bets to Buy as Markets Brave Coronavirus
by Manaswita Ghosh Dutta
Global markets lost $6 trillion in the week ended Feb 29 as coronavirus triggered sharp selloff. Here's how to play the dip.
Trump Asks Pharma Firms to Step Up Coronavirus Vaccine Work
by Kinjel Shah
President Donald Trump asks pharmaceutical companies working on making vaccines or treatments for coronavirus to accelerate development.
5 Biotechs That Escaped the Coronavirus Onslaught Last Week
by Kinjel Shah
Here we discuss 5 biotech stocks that outperformed the industry amid the U.S. market slump.
The Zacks Analyst Blog Highlights: Co-Diagnostics, VAXART, Sprint, Stamps.com and Uniti
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Co-Diagnostics, VAXART, Sprint, Stamps.com and Uniti